Boston Scientific Corp. shares climbed after it won approval for ... Analysts also noted that revenue from spinal products was below expectations. The stock was off marginally in recent action to $58.22.
Investors have given a vote of confidence to current management’s recent turnaround efforts. Boston Scientific’s stock price has more than doubled this year, after about four years in which it had been stuck in the single-digit range. …
Mr. Daniel J. Brennan is Chief Financial Officer, Executive Vice President of the Company. He is responsible for several Company functions, including Global Controllership, Global Internal Audit, Corporate Finance, Treasury, Corporate Tax, …
On Wednesday Medsafe said 17 products from three companies – Boston
A smaller company, Boston Scientific Corp (NYSE:BSX), with a market cap of $26B ... Some companies are doing truly great. Stock picking is mandatory in this stage, until the biotech index shows a confirmed breakout, at which point …
His last position at Boston Scientific was president ... option grants with an aggregate grant date fair value of $176,400 of the Company's common stock, pursuant to the terms of the Company's Board of Directors Non-Employee Director …
Boston Scientific’s stock still hasn’t fully recovered from its bidding war with rival Johnson & Johnson over Guidant: The stock currently trades below $14 a share, compared with a $25-per-share range at the start of 2006. Tobin has spent …
The founders said the sales were automatic trades triggered by the need to cover collateralized loans, and don’t reflect on the company.
Boston Scientific plans to argue that Guidant did not knowingly violate the agreement, according to court papers. It has also questioned whether J&J can prove it lost money. J&J's stock has soared since, while Boston Scientific's has …